8 – Intro to Clinical PK Flashcards

1
Q

3 options when deciding drug dose and regime

A
  1. Follow drug label (MOST OFTEN)
  2. Look at a research paper
  3. Individualize treatment for specific patient (usually more ‘extreme’ circumstances)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Pharmacodynamics

A
  • Dose is NOT proportional to effect
  • Often when increase dose=not get a better effect and just get closer to the toxic effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Therapeutic window

A
  • Range between minimum EFFECTIVE and minimum TOXIC plasma concentrations in an INDIVIDUAL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Therapeutic range

A
  • Plasma concentration range in POPULATION likely to produce a desired effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Clinical limitations of PK data

A
  • Most studies are done on blood (plasma), but most drugs don’t work in the blood
    o Need to extrapolate from blood levels to tissue levels
  • Not all drug use is systemic (ex. skin lesion, put drug on the skin)
  • Studies done on small groups of similar animals (Ex. effects of age, gender, sex, body type, pregnancy, lactation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Penicillin for UTI

A
  • Works well because the kidneys get rid of it so much, so there is ton in the urine!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Tulathromycin: plasma vs. tissue drug concentration

A
  • Much higher in the lung than the blood plasma
  • Also drops off more slowly
  • *may be good for treating pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Drugs (ex. moxidectin): thin vs. fat animals

A
  • Stays in the fat=last longer in the body
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

If you were to get a toxic effect, when would it be?

A
  • Cmax = early on!
    o Then concentration drops of in a ‘curve’
  • Some drugs: need to give them slowly to not get a toxic effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

AUC

A
  • Area under the curve
  • Measure of drug and drug time in the body
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

If you infuse a drug at a constant rate

A
  • Concentration will rise logarithmically to reach a steady state
  • Final concentration is related to RATE OF INFUSION
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How long does it take to reach steady state?

A
  • Based on half-life of the drug
  • Ex. ~7 half-lives
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Can you get the drug concentration to steady state faster?

A
  • Loading dose
    o Rapid IV bolus followed by sustained infusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Loading dose equation

A
  • =desired concentration x volume of distribution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Volume of distribution

A
  • =total dose of drug / C max
  • L/kg
    *gives you an idea of how drug distributes in the body
    Ex. if 0.6= in extracellular and intracellular fluid (60% of body is water)
    Ex. if more than 1=somewhere else in the body and not in the blood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When you give a drug any other route than IV…

A
  • It needs to be absorbed into the plasma
    o Typically happens relatively quickly (Cmax)
    o Tmax will not be 0
  • ‘triangle’ at front of the curve
  • Not all of the drug will get into the bloodstream
16
Q

Route of administration affects

A
  • Absorption phase
  • Bioavailability
  • Sustained release
17
Q

Bioavailability: IV vs oral (flunixin)

A
  • Elimination rate does NOT change
  • Bioavailability(F) = AUC oral / AUC IV
  • *how much of the drug gets into the blood
18
Q

Sustained release (ex. penicillin)

A
  • Half life: 20mins = drops off very fast
  • Procaine (salt) penicillin: ‘holds’ onto penicillin
    o Doesn’t spike as fast or as high
    o Eliminated, but it is slowly being released for SUSTAINED RELEASE
    *pseudo-infusion
19
Q

Flip-flop kinetics

A
  • Describes situation where a ‘depot’ injection is SLOWLY absorbed over time
  • Apparent elimination rate is controlled by the absorption rate from the depot
    *LONG ACTING DRUGS
20
Q

Dosage interval more frequently than half-life

A
  • Drug will slowly increase over time (still considered steady state, 4 half-lives to get there)
  • *those with a narrow window (want less variation between Cmax and Cmin)
  • Ex. dog with epilepsy (slowly increase to reach a therapeutic level)
  • ACCUMULATION WITH MINIMAL FLUCTUATION
  • Missing one dose has minimal impact on plasma concentration
  • May need a loading dose
21
Q

Dosage interval at same time as half-life

A
  • A little bit of accumulation, but more variation between Cmax and Cmin
22
Q

Dosage interval less frequently than half-life

A
  • Give the drug, it gets eliminated: REPEAT
  • Not much accumulation
  • Very massive spread between Cmax and Cmin
  • Missing a dose greatly affects concentration
  • Minimal lag time to achieve desired concentration
  • Ex. penicillin
23
Q

When can you change the dose?

A
  • If giving something orally, may increase dose as the bioavailability is reduced (use relative bioavailability)
  • Kidney or liver disease
    o Enzyme inhibition=decrease dose
    o Increased clearance due to enzyme induction=increase dose
24
Q

When can you change the dose interval?

A
  • Based on therapeutic drug monitoring (ex. phenobarb for seizures)
  • Based on likely changes in drug clearance (ex. renal or hepatic failure)
25
Q

Drug formulation is optimized based on

A
  • Pharmacokinetics
  • Pharmacodynamics
    *both need to be well known
26
Q

Knowing which drug is ‘better’

A
  • PK parameters do NOT indicate safety or efficacy
27
Q

Limitations of PK data: volume of distribution

A
  • Just a RATIO
  • Don’t know what tissues the drug may be in
  • Higher does NOT mean it works better
28
Q

Limitations of PK data: half-life

A
  • Elimination half-life
  • Longer does NOT mean better
  • Elimination from tissues may not be the same as in the plasma
29
Q

Limitations of PK data: plasma concentrations

A
  • May not be relevant to tissue drug concentrations
30
Q

Limitations of PK data: PK/PD models

A
  • Highly variable between studies
  • Numbers are NOT absolute
  • Only PREDICTIVE
    o Need to have a randomized controlled clinical trial
31
Q

Summary of PK for vets

A
  • Can’t rely on them solely, NEED research
  • Know where the drug is going, how it is eliminated and how long it sticks around
  • Can help modify things when you need to